-+ 0.00%
-+ 0.00%
-+ 0.00%

ELEVAR THERAPEUTICS RESUBMITS NEW DRUG APPLICATION TO FDA FOR COMBINATION OF CAMRELIZUMAB PLUS RIVOCERANIB FOR USE AS A FIRST-LINE TREATMENT OPTION FOR UNRESECTABLE OR METASTATIC HEPATOCELLULAR CARCINOMA

Reuters·10/14/2026 15:18:02